Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state.

Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H.

Drug Des Devel Ther. 2014 Jun 25;8:851-8. doi: 10.2147/DDDT.S62176. eCollection 2014.

2.
3.

Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension.

Deschamps B, Musaji N, Gillespie JA.

Int J Nanomedicine. 2009;4:185-92. Epub 2009 Sep 10.

4.

Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers.

Kim YH, Choi HY, Jin S, Noh YH, Kim MJ, Park HJ, Lim HS, Bang K, Lee SH, Bae KS.

Clin Ther. 2015 Feb 1;37(2):439-47. doi: 10.1016/j.clinthera.2014.09.022. Epub 2014 Oct 23.

PMID:
25450470
6.
7.

Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.

Chen C, Bujanover S, Kareht S, Rapoport AM.

Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.

PMID:
25546369
8.

Nanomemulsion of megestrol acetate for improved oral bioavailability and reduced food effect.

Li Y, Song CK, Kim MK, Lim H, Shen Q, Lee DH, Yang SG.

Arch Pharm Res. 2015 Oct;38(10):1850-6. doi: 10.1007/s12272-015-0604-9. Epub 2015 Apr 18.

PMID:
25893430
9.

The science of megestrol acetate delivery: potential to improve outcomes in cachexia.

Femia RA, Goyette RE.

BioDrugs. 2005;19(3):179-87. Review.

PMID:
15984902
10.

Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.

Van Harken DR, Pei JC, Wagner J, Pike IM.

Antimicrob Agents Chemother. 1997 Nov;41(11):2480-3.

11.

Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.

Ha ES, Kim JS, Baek IH, Yoo JW, Jung Y, Moon HR, Kim MS.

Drug Des Devel Ther. 2015 Aug 4;9:4269-77. doi: 10.2147/DDDT.S90706. eCollection 2015.

12.

Improved bioavailability of a micronized megestrol acetate tablet formulation in humans.

Farinha A, Bica A, Tavares P.

Drug Dev Ind Pharm. 2000 May;26(5):567-70.

PMID:
10789071
13.

The effect of food on the absorption and pharmacokinetics of rivaroxaban.

Stampfuss J, Kubitza D, Becka M, Mueck W.

Int J Clin Pharmacol Ther. 2013 Jul;51(7):549-61. doi: 10.5414/CP201812.

PMID:
23458226
14.

The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study.

Simmons SF, Walker KA, Osterweil D.

J Am Med Dir Assoc. 2005 May-Jun;6(3 Suppl):S5-11.

PMID:
15890297
15.

The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study.

Simmons SF, Walker KA, Osterweil D.

J Am Med Dir Assoc. 2004 Jan-Feb;5(1):24-30.

PMID:
14706125
16.

Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients.

Graham KK, Mikolich DJ, Fisher AE, Posner MR, Dudley MN.

J Acquir Immune Defic Syndr. 1994 Jun;7(6):580-6.

PMID:
8176641
18.

Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers.

Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ.

Drug Des Devel Ther. 2014 Jan 15;8:123-8. doi: 10.2147/DDDT.S53027. eCollection 2014.

20.

Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.

Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, Kim K, Park JW, Yoon H, Lee J, Park MS, Park K.

Clin Ther. 2011 Dec;33(12):2038-53. doi: 10.1016/j.clinthera.2011.10.024. Epub 2011 Nov 29.

PMID:
22129569
Items per page

Supplemental Content

Write to the Help Desk